These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25490610)

  • 1. Association between hepatitis C virus and opioid use while in buprenorphine treatment: preliminary findings.
    Murphy SM; Dweik D; McPherson S; Roll JM
    Am J Drug Alcohol Abuse; 2015 Jan; 41(1):88-92. PubMed ID: 25490610
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial.
    Woody GE; Poole SA; Subramaniam G; Dugosh K; Bogenschutz M; Abbott P; Patkar A; Publicker M; McCain K; Potter JS; Forman R; Vetter V; McNicholas L; Blaine J; Lynch KG; Fudala P
    JAMA; 2008 Nov; 300(17):2003-11. PubMed ID: 18984887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus Testing and Treatment Among Persons Receiving Buprenorphine in an Office-Based Program for Opioid Use Disorders.
    Carey KJ; Huang W; Linas BP; Tsui JI
    J Subst Abuse Treat; 2016 Jul; 66():54-9. PubMed ID: 26988423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling longitudinal changes in buprenorphine treatment outcome for opioid dependence.
    Saleh MI
    Pharmacopsychiatry; 2014 Nov; 47(7):251-8. PubMed ID: 25321188
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Retention in buprenorphine treatment is associated with improved HCV care outcomes.
    Norton BL; Beitin A; Glenn M; DeLuca J; Litwin AH; Cunningham CO
    J Subst Abuse Treat; 2017 Apr; 75():38-42. PubMed ID: 28237052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Buprenorphine Implants on Illicit Opioid Use Among Abstinent Adults With Opioid Dependence Treated With Sublingual Buprenorphine: A Randomized Clinical Trial.
    Rosenthal RN; Lofwall MR; Kim S; Chen M; Beebe KL; Vocci FJ;
    JAMA; 2016 Jul; 316(3):282-90. PubMed ID: 27434441
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine implants for treatment of opioid dependence: a randomized controlled trial.
    Ling W; Casadonte P; Bigelow G; Kampman KM; Patkar A; Bailey GL; Rosenthal RN; Beebe KL
    JAMA; 2010 Oct; 304(14):1576-83. PubMed ID: 20940383
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of a Payer-Mandated Decrease in Buprenorphine Dose on Aberrant Drug Tests and Treatment Retention Among Patients with Opioid Dependence.
    Accurso AJ; Rastegar DA
    J Subst Abuse Treat; 2016 Feb; 61():74-9. PubMed ID: 26639639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A trial of integrated buprenorphine/naloxone and HIV clinical care.
    Sullivan LE; Barry D; Moore BA; Chawarski MC; Tetrault JM; Pantalon MV; O'Connor PG; Schottenfeld RS; Fiellin DA
    Clin Infect Dis; 2006 Dec; 43 Suppl 4():S184-90. PubMed ID: 17109305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users.
    Tsui JI; Evans JL; Lum PJ; Hahn JA; Page K
    JAMA Intern Med; 2014 Dec; 174(12):1974-81. PubMed ID: 25347412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Buprenorphine tapering schedule and illicit opioid use.
    Ling W; Hillhouse M; Domier C; Doraimani G; Hunter J; Thomas C; Jenkins J; Hasson A; Annon J; Saxon A; Selzer J; Boverman J; Bilangi R
    Addiction; 2009 Feb; 104(2):256-65. PubMed ID: 19149822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Naltrexone-facilitated buprenorphine discontinuation: a feasibility trial.
    Dakwar E; Kleber HD
    J Subst Abuse Treat; 2015 Jun; 53():60-3. PubMed ID: 25819700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus infection and pain sensitivity in patients on methadone or buprenorphine maintenance therapy for opioid use disorders.
    Tsui JI; Lira MC; Cheng DM; Winter MR; Alford DP; Liebschutz JM; Mao J; Edwards RR; Samet JH
    Drug Alcohol Depend; 2015 Aug; 153():286-92. PubMed ID: 26048638
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug interactions between buprenorphine, methadone and hepatitis C therapeutics.
    Ogbuagu O; Friedland G; Bruce RD
    Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):721-31. PubMed ID: 27140427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A chart review based comparative study of retention rates for two dispensing regimens for buprenorphine for subjects with opioid dependence at a tertiary care substance use disorder treatment center.
    Balhara YP
    J Opioid Manag; 2014; 10(3):200-6. PubMed ID: 24944070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial.
    Marsch LA; Bickel WK; Badger GJ; Stothart ME; Quesnel KJ; Stanger C; Brooklyn J
    Arch Gen Psychiatry; 2005 Oct; 62(10):1157-64. PubMed ID: 16203961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis after intravenous injection of sublingual buprenorphine in acute hepatitis C carriers: report of two cases of disappearance of viral replication after acute hepatitis.
    Peyrière H; Tatem L; Bories C; Pageaux GP; Blayac JP; Larrey D
    Ann Pharmacother; 2009 May; 43(5):973-7. PubMed ID: 19383935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of an injection depot formulation of buprenorphine: placebo comparison.
    Sigmon SC; Wong CJ; Chausmer AL; Liebson IA; Bigelow GE
    Addiction; 2004 Nov; 99(11):1439-49. PubMed ID: 15500597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of HCV seropositive status on buprenorphine pharmacokinetics in opioid-dependent individuals.
    Masson CL; Rainey PM; Moody DE; McCance-Katz EF
    Am J Addict; 2014; 23(1):34-40. PubMed ID: 24313239
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A controlled trial of daily versus thrice-weekly buprenorphine administration for the treatment of opioid dependence.
    Pérez de los Cobos J; Martin S; Etcheberrigaray A; Trujols J; Batlle F; Tejero A; Queraltó JM; Casas M
    Drug Alcohol Depend; 2000 Jun; 59(3):223-33. PubMed ID: 10812283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.